aTyr reports Q3 results; Phase 3 efzofitimod miss but plans FDA meeting

aTYR PHARMA INC

2025-Q3 EPS reported -$0.66 vs consensus -$0.19 ▼ miss (-252.4%)

Phase 3 EFZO-FIT missed primary endpoint of corticosteroid dose reduction at week 48; 5.0 mg/kg showed benefit on multiple quality-of-life measures.
Company plans FDA meeting in Q1 2026 to discuss path forward for efzofitimod in pulmonary sarcoidosis.
Phase 2 EFZO-CONNECT enrollment in SSc-ILD expected to complete H1 2026; interim data reported Q2 2025.
Cash, equivalents, restricted cash and investments $92.9M as of Sep 30, 2025.
R&D expenses $22.1M, G&A $4.8M for Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.